What is Righteye?
Founded in 2012 and headquartered in Bethesda, Maryland, RightEye is a health technology enterprise that utilizes advanced eye-tracking and gamified interfaces to revolutionize vision diagnostics. The company's core offering, the RightEye EyeQ platform, provides healthcare providers with objective, data-backed insights into brain health, reading disorders, and ocular performance. By digitizing the diagnostic process, RightEye enables clinicians to generate actionable reports in minutes, facilitating a more precise approach to patient care and treatment monitoring. Beyond clinical applications, the company's technology is deployed in high-stakes environments such as military training, law enforcement, and elite athletics, where visual precision and reaction time are critical performance indicators. The firm's ability to bridge the gap between complex neurological data and user-friendly software has established it as a key player in the burgeoning digital health landscape.
How much funding has Righteye raised?
Righteye has raised a total of $10.2M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$7.3M
Debt
$350K
Debt
$492K
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2017): $7.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $492K featuring PPP
Key Investors in Righteye
PPP
Public-Private Partnership
Undisclosed Private Equity
Institutional capital partners focused on long-term growth and the scaling of innovative health technology platforms.
Undisclosed Private Equity
Strategic investment entities specializing in the development of early-stage medical and diagnostic hardware solutions.
What's next for Righteye?
Looking ahead, RightEye is positioned to capitalize on the increasing demand for objective, non-invasive diagnostic tools in the global healthcare market. The strategic deployment of recent capital suggests a focus on expanding the reach of its Scanning Precision Eyesight Capture Solution and enhancing its reading disorder identification tools. As the company scales, it will likely prioritize the integration of its cloud-based platform into broader electronic health record systems, further embedding its technology into the standard of care. Furthermore, the continued application of its proprietary algorithms in specialized sectors like private security and professional sports indicates a diversification strategy aimed at maximizing the utility of its ocular data sets. By maintaining its focus on science-based, metric-driven innovation, RightEye is well-equipped to navigate the complexities of the health-tech sector and drive long-term value for its stakeholders.
See full Righteye company page
